Setmelanotide

In plain language

Setmelanotide is a daily injection for obesity caused by rare genetic errors in a brain pathway that controls hunger, sold as Imcivree. It is approved for several of these syndromes, including POMC and LEPR deficiency and Bardet-Biedl syndrome.

It switches on the melanocortin-4 receptor (MC4R), a master switch in the brain's appetite circuit that these patients cannot signal through normally. Restoring the signal reduces the drive to eat and produces substantial weight loss in this specific population, though it is not a general obesity drug.

For students

Setmelanotide is a cyclic lactam heptapeptide MC4R agonist (about 1,117 Da) with a design that achieves high MC4R potency and central nervous system penetration after subcutaneous injection. MC4R signaling in the paraventricular hypothalamus and other sites integrates leptin-melanocortin inputs into satiety; loss-of-function mutations upstream (POMC, PCSK1, LEPR) or at the receptor itself (MC4R deficiency, not an approved indication for the drug) produce hyperphagia and severe early-onset obesity.

Phase 3 trials in POMC/PCSK1/LEPR deficiency showed substantial weight loss (about 25.6% at 1 year in the combined cohorts) and marked hyperphagia reduction; trials in Bardet-Biedl syndrome showed more modest but significant effects (about 5% weight reduction and hunger improvement) and in Alstrom syndrome similarly modest results. The FDA approved it in 2020 for POMC, PCSK1 and LEPR deficiency obesity in patients 6 and older, and in 2022 for BBS. Adverse effects include skin hyperpigmentation and spontaneous penile erection; monitoring for these and for depression is advised.

For researchers and instructors

Biochemistry. Selective MC4R agonism with central penetration, distinct from the older non-selective melanocortin agonists (like the discontinued melanotan II family), is the design lesson; the molecule avoids the MC3R activity that contributed to prior failures.

Pharmacology. Daily subcutaneous 2 mg (or weight-based 3 mg in pediatric BBS); drug interactions via CYP2B6 induction (a unique consideration for peptides); hyperpigmentation is cosmetic and reversible.

Human evidence. Phase 3 trials (n=63 POMC/PCSK1/LEPR cohorts; n=61 BBS) with responsive and non-responsive genetic subgroups are peer-reviewed; the pathway-genotype linkage is the strongest in obesity pharmacotherapy.

Teaching point. The first obesity drug built on a genetically defined mechanism, teaching precision medicine in metabolism and the difference between pathway-specific and population-level obesity treatment.